Form 4: Palisade Bio, Inc.: Chief Medical Officer Mitchell Jones Acquires Stock Options and Restricted Stock Units

Chief Medical Officer Mitchell Lawrence Jones reports acquisition of stock options and restricted stock units in Palisade Bio, Inc.

Summary

• Mitchell Lawrence Jones, Chief Medical Officer of Palisade Bio, Inc., filed a Form 4 on February 13, 2025, reporting transactions related to the company's securities.
• On February 11, 2025, Jones acquired 29,000 stock options with an exercise price of $1.13, vesting quarterly over three years starting May 11, 2025.
• Additionally, Jones acquired 24,000 restricted stock units (RSUs), each representing one share of common stock, vesting in three equal annual installments beginning February 11, 2026.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects standard compensation practices. The insider's acquisition of shares suggests a degree of confidence, but it's a routine event.

Positives

• The acquisition of stock options and RSUs by the Chief Medical Officer could indicate confidence in the company's future performance.

Future Outlook

The vesting schedules for both the stock options and RSUs are contingent upon the Reporting Person's continuous service to the Issuer.

Industry Context

Form 4 filings are standard practice for company insiders and provide transparency into their transactions involving the company's securities.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the insider's increased stake in the company.

Key Dates

Keywords

Form 4, Palisade Bio, Inc., Stock Options, Restricted Stock Units, Mitchell Lawrence Jones, Chief Medical Officer, Beneficial Ownership, PALI